Skip to main content Skip to main navigation menu Skip to site footer
Journal of Commercial Biotechnology
  • Submissions
  • Subscribe
  • Current
  • Archives
  • Announcements
  • Search
  • About
    • About the Journal
    • Editorial Team
    • Privacy Statement
    • Contact
Search
  • Register
  • Login
  1. Home /
  2. Archives /
  3. Vol. 21 No. 3 (2015)

Vol. 21 No. 3 (2015)

Published: 2015-07-01

Commentary

  • Combating a Global Pandemic of Weak, Adulterated, and Fake Drugs

    Menghis Bairu
    • PDF
  • The Globetrotting Regulator

    Peter J. Pitts
    • PDF
  • FDA: Is Off-Label on the Table?

    Peter Pitts
    • PDF
  • A ‘Genetically Engineered’ Label: Way More Expensive Than You Think

    Henry I Miller, Graham Brookes
    • PDF

Articles

  • Cannabis-Derived Pharmaceuticals

    Clifford S Mintz, Evan Nison, AJ Fabrizio
    • PDF
  • Venture Capitalists as gatekeepers for Biotechnological Innovation

    Kenneth Fernald, Ruud Hoeben, Eric Claassen
    • PDF

From the Boardroom

  • BioTime’s bid to end age-related disease: A look at CEO Michael West’s Vision

    Ian C. Clift
    • PDF

Legal and Regulatory Updates

  • EU Legal & Regulatory Update – May 2015

    Henry Elliott
    • PDF

Conference Report

  • Innovation Landscape, Deal-making Strategies and Success Stories

    Vasu Pestonjamasp
    • PDF

Subscription

Login to access subscriber-only resources.

Make a Submission

Make a Submission

Current Issue

  • Atom logo
  • RSS2 logo
  • RSS1 logo

ISSN: 1462-8732 / eISSN 1478-565X

More information about the publishing system, Platform and Workflow by OJS/PKP.